Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$1.43 USD
+0.01 (0.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.44 +0.01 (0.70%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Checkpoint Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 1 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 1 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 52 | 59 | 57 | 24 | 27 |
Income After Depreciation & Amortization | -52 | -58 | -57 | -23 | -25 |
Non-Operating Income | 0 | -4 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -52 | -63 | -57 | -23 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -63 | -57 | -23 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -52 | -63 | -57 | -23 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -58 | -57 | -23 | -25 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -52 | -58 | -57 | -23 | -25 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.74 | 8.84 | 7.60 | 5.58 | 3.53 |
Diluted EPS Before Non-Recurring Items | -3.17 | -7.09 | -7.50 | -4.10 | -7.00 |
Diluted Net EPS (GAAP) | -3.17 | -7.09 | -7.50 | -4.10 | -7.00 |
Fiscal Year end for Checkpoint Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.01 | 0.03 | 0.03 | 0.04 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.01 | 0.03 | 0.03 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 10.18 | 7.74 | 16.23 | 18.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -10.17 | -7.71 | -16.20 | -18.08 |
Non-Operating Income | NA | -8.96 | 1.98 | -0.33 | 7.61 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -19.13 | -5.72 | -16.52 | -10.47 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -19.13 | -5.72 | -16.52 | -10.47 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -19.13 | -5.72 | -16.52 | -10.47 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 17.31 | 19.99 | 15.70 | 11.75 |
Diluted EPS Before Non-Recurring Items | NA | -1.10 | -0.29 | -1.05 | -0.89 |
Diluted Net EPS (GAAP) | NA | -0.94 | -0.29 | -1.05 | -0.89 |